Novel therapies based on enhancement of gut innate immunity in inflammatory bowel disease

• LATINNE D, FIASSE R: New insights into the cellular immunology of the intestine in relation to the pathophysiology of inflammatory bowel disease. Acta Gastroenterol. Belg. (2006) 69:393-405.
   PubMed Web of Science ®Google Scholar
• VAN LIMBERGEN J, RUSSELL RK, NIMMO ER et al.: Genetics of the innate immune response in inflammatory bowel disease. Inflamm. Bowel Dis. (2007) 13:338-355.
   PubMed Web of Science ®Google Scholar
• XAVIER RJ, PODOLSKY DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature (2007) 448:427-434.
   PubMed Web of Science ®Google Scholar
• HUGOT JP, CHAMAILLARD M, ZOUALI H et al.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 411:599-603.
   PubMed Web of Science ®Google Scholar
• OGURA Y, BONEN DK, INOHARA N et al.: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 411:603-606.
   PubMed Web of Science ®Google Scholar
• INOUE N, TAMURA K, KINOUCHI Y et al.: Lack of common NOD2 variants in Japanese patients with Crohns' disease. Gastroenterology (2002) 123:86-91.
   PubMed Web of Science ®Google Scholar
• BRAAT H, STOKKERS P, HOMMES T et al.: Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohns's disease patients. J. Mol. Med. (2005) 83:601-609.
   PubMed Web of Science ®Google Scholar
• FRANCHIMONT D, VERMEIRE S, EL HOUSNI H et al.: Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut (2004) 53:987-992.
   PubMed Web of Science ®Google Scholar
• GEWIRTZ AT, VIJAY-KUMAR M, BRANT SR et al.: Dominant-negative TLR5 polymorphism reduces adaptive immune responses to flagellin and negatively associates with Crohns' disease. Am. J. Physiol. Gastrointest. Liver Physiol. (2006) 290:G1157-G1163.
   PubMed Web of Science ®Google Scholar
• PRESCOTT NJ, FISHER SA, FRANKE A et al.: A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohns's disease and is independent of CARD15 and IBD5. Gastroenterology (2007) 132:1665-1671.
   PubMed Web of Science ®Google Scholar
• BERNSTEIN CN: Novel therapeutics in inflammatory bowel disease. Expert Opin. Ther. Patents (2001) 11:1081-1096.
   Web of Science ®Google Scholar
• ARRIETA MC, BISTRITZ L, MEDDINGS JB: Alterations in intestinal permeability. Gut (2006) 55:1512-1520.
   PubMed Web of Science ®Google Scholar
• IRVINE EJ, MARSHALL JK: Increased intestinal permeability precedes the onset of Crohns' disease in a subject with familial risk. Gastroenterology (2000) 119:1740-1744.
   PubMed Web of Science ®Google Scholar
• MIELE E, PASCARELLA F, QUAGLIETTA et al.: Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis. Aliment. Pharmacol. Ther. (2007) 25:933-939.
   PubMed Web of Science ®Google Scholar
• ANDOH A, FUJIYAMA Y: Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J. Gastroenterol. (2006) 12:4452-4460.
   PubMed Web of Science ®Google Scholar
• GUARNER F, BORDET-SICARD R, BRANDZAEG P et al.: Mechanisms of disease: the hygiene hypothesis revisited. Nat. Clin. Pract. Gastroenterol. Hepatol. (2006) 3:275-283.
   PubMedGoogle Scholar
• MARTEAU P, LEPAGE P, MANGIN I et al.: Review article: gut flora in inflammatory bowel disease. Aliment. Pharmacol. Ther. (2004) 20(Suppl. 4):18-23.
   PubMed Web of Science ®Google Scholar
• SWIDSINSKI A, LADHOFF A, PERNTHALER A et al.: Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 122:44-54.
   PubMed Web of Science ®Google Scholar
• KLEESSEN B, KROESEN AJ, BUHR HJ, BLAUT M: Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand. J. Gastroenterol. (2002) 37:1034-1041.
   PubMed Web of Science ®Google Scholar
• BRAUN J: Unsettling facts of life: bacterial commensalism, epithelial adherence, and inflammatory bowel disease. Gastroenterology (2002) 122:228-229.
   PubMed Web of Science ®Google Scholar
• SONNENBURG JL, ANGENENT LT, GORDON JI: Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? Nat. Immunol. (2004) 5:569-573.
   PubMed Web of Science ®Google Scholar
• SWIDSINSKI A, LOENING-BAUCKE V, THEISSIG F et al.: Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut (2007) 56:343-350.
   PubMed Web of Science ®Google Scholar
• VAN KLINKEN BJ-W, VAN DER WAL J-WG, EINERHAND AWC et al.: Sulphation and secretion of the predominant secretory human colonic mucin MUC2 in ulcrative colitis. Gut (1999) 44:387-393.
   PubMed Web of Science ®Google Scholar
• TAUPIN D, PODOLSKY DK: Trefoil factors: initiators of mucosal healing. Nat. Rev. Mol. Cell. biol. (2003) 4:721-732.
   PubMed Web of Science ®Google Scholar
• FINNIE, DWARAKANATH AS, TAYLOR BA, RHODES JM: Colonic mucin synthesis is increased by sodium buryrate, a short chain fatty acid (SCFA). Gut (1995) 36:93-99.
   PubMed Web of Science ®Google Scholar
• HARIG JM, SOERGEL KH, KOMOROWSKI RA, WOOD CM: Treatment of diversion colitis with short-chain-fatty acid irrigation. N. Engl. J. Med. (1989) 320:23-28.
   PubMed Web of Science ®Google Scholar
• KOTLOWSKI R, BERNSTEIN CN, SEPEHRI S, KRAUSE DO: High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut (2007) 56:669-675.
   PubMed Web of Science ®Google Scholar
• HENDERSON IR, NATARO JP: Virulence functions of autotransporter proteins. Infect. Immun. (2001) 69:1231-1243.
   PubMed Web of Science ®Google Scholar
• RHODES JM: The role of Escherichia coli in inflammatory bowel disease. Gut (2007) 56:610-612.
   PubMed Web of Science ®Google Scholar
• LIU Y, VAN KRUININGEN HJ, WEST AB et al.: Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology (1995) 108:1396-1404.
   PubMed Web of Science ®Google Scholar
• JERGENS AE, WILSON-WELDER JH, DORN A et al.: Helicobcter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut (2007) 56:934-940.
   PubMed Web of Science ®Google Scholar
• ZEISSIG S, BÜRGEL D, GÜNZEL D et al.: Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut (2007) 56:61-72.
   PubMed Web of Science ®Google Scholar
• WEBER CR, TURNER JR: Inflammatory bowel disease: is it really just another break in the wall? Gut (2007) 56:6-8.
   PubMed Web of Science ®Google Scholar
• ZOLOTAREVSKY Y, HECHT G, KOUTSOURIS A et al.: A membrane-permeable peptide that inhibits MLC kinase restores barrier function in invitro models of intestinal disease. Gastroenterology (2002) 123:163-172.
   PubMed Web of Science ®Google Scholar
• MA TY, BOIVIN MA, YE D et al.: Mechanism of TNF-α modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 288:G422-G430.
   PubMed Web of Science ®Google Scholar
• WANG F, GRAHAM WV, WANG Y et al.: Interferon-gamma and TNF-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression. Am. J. Pathol. (2005) 166:409-419.
   PubMed Web of Science ®Google Scholar
• KAGNOFF MF, ECKMANN L: Epithelial cells as sensors for microbial infection. J. Clin. Invest. (1997) 100:6-10.
   PubMed Web of Science ®Google Scholar
• BLAIR SA, KANE SV, CLAYBURGH DR et al.: Epithelial myosin light chain kinase expression and activity are upregulated in inflammatory bowel disease. Lab. Invest. (2006) 86:191-201.
   PubMed Web of Science ®Google Scholar
• CRISTOFARO P, OPAL SM: Role of Toll-like receptors in infection and immunity. Clinical implications. Drugs (2006) 66:15-29.
   PubMed Web of Science ®Google Scholar
• CARIO E, GERKEN G, PODOLSKY DK: Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology (2007) 132:1359-1374.
   PubMed Web of Science ®Google Scholar
• HAUSMANN M, KIESSLING S, MESTERMANN S et al.: Toll-like receptors 2 and 4 are upregulated during intestinal inflammation. Gastroenterology (2002) 122:1987-2000.
   PubMed Web of Science ®Google Scholar
• CARIO R, PODOLSKY DK: Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immunol. (2000) 68:7010-7017.
   PubMed Web of Science ®Google Scholar
• ARNOTT IDR, HO G-T, NIMMO ER, SATSANGI J: Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe. Gut (2005) 54:308-309.
   PubMedGoogle Scholar
• WATANABE T, KITANI A, MURAY PJ, STROBER W: NOD2 is a negative regulator of toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. (2004) 5:800-808.
   PubMed Web of Science ®Google Scholar
• COMALADA M, PEPPELENBOSCH MP: Impaired innate immunity in Crohn's disease. Trends Mol. Med. (2006) 12:397-399.
   PubMed Web of Science ®Google Scholar
• ROSENSTIEL P, FANTINI M, BRÄUTIGAM K et al.: TNF-α and IFN-γ regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology (2003) 124:1001-1009.
   PubMed Web of Science ®Google Scholar
• SCHMID D, DENGJEL J, SCHOOR O et al.: Autophagy in innate and adaptive immunity against intracellular pathogens. J. Mol. Med. (2006) 84:194-202.
   PubMed Web of Science ®Google Scholar
• GANZ T, LEHRER RI: Defensins. Curr. Opin. Immunol. (1994) 6:584-589.
   PubMed Web of Science ®Google Scholar
• WEHKAMP J, SCHMID M, STANGE EF: Defensins and other antimicrobial peptides in inflammatory bowel disease. Curr. Opin. Gastroenterol. (2007) 23:370-378.
   PubMed Web of Science ®Google Scholar
• MALLEGOL J, VAN NIEL G, LEBRETON C et al.: T84-intestinal epithelial exosomes bear MHC class II/peptide complexes potentiating antigen presentation by dendritic cells. Gastroenterology (2007) 132:1866-1876.
   PubMed Web of Science ®Google Scholar
• DUBUCQUOY L, ROUSSEAUX C, THURU X et al.: PPAR-γ as a new therapeutic target in inflammatory bowel disease. Gut (2006) 55:1341-1349.
   PubMed Web of Science ®Google Scholar
• PONFERRADA A, CASO JR, ALOU L et al.: The role of PPAR-γ on restoration of colonic homeostasis after experimental stress-induced inflammation and dysfunction. Gastroenterology (2007) 132:1791-1803.
   PubMed Web of Science ®Google Scholar
• SUGAWARA K, OLSON TS, MOSKALUK CA et al.: Linkage to peroxysome proliferator-activated receptor-γ in SAMP1/YiFc mice and in human Crohn's disease. Gastroenterology (2005) 128:351-360.
   PubMed Web of Science ®Google Scholar
• LIBIOULLE C, LOUIS E, HANSOUL S et al.: Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. Plos Genet. (2007) 3:E58.
   PubMed Web of Science ®Google Scholar
• GIRONELLA M, IOVANNA JL, SANS M et al.: Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut (2005) 54:1244-1253.
   PubMed Web of Science ®Google Scholar
• O'MORAIN CA: Crohn's disease: treatment and pathogenesis. CRC Press, Inc. (1987).
   Google Scholar
• MARKS DJB, HARBORD MWN, MACALLISTER R et al.: Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet (2006) 367:668-678.
   PubMed Web of Science ®Google Scholar
• HARBORD MWN, MARKS DJB, FORBES A et al.: Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment. Pharmacol. Ther. (2006) 24:651-660.
   PubMed Web of Science ®Google Scholar
• PEYRIN-BIROULET L, CHAMAILLARD M, GONZALEZ F et al.: Mesenteric fat in Crohn's disease: genetic hallmark or an innocent bystander? Gut (2007) 56:577-583.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO K, KIYOHARA T, MURAYAMA Y et al.: Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut (2005) 54:789-796.
   PubMed Web of Science ®Google Scholar
• FAYAD R, PINI M, SENNELLO JA et al.: Adiponectin deficiency protects mice from chemically induced colonic inflammation. Gastroenterology (2007) 132:601-614.
   PubMed Web of Science ®Google Scholar
• NEURATH MF: IL-23: a master regulator in Crohn's disease. Nat. Med. (2007) 13:26-28.
   PubMed Web of Science ®Google Scholar
• DUERR RH, TAYLOR KD, BRANT SR et al.: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science (2006) 314:1461-1463.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR: Is Crohn's disease due to defective immunity? Gut (2007) 56:2-5.
   PubMed Web of Science ®Google Scholar
• STREMMEL W, MERLE U, ZAHN A et al.: Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut (2005) 54:966-971.
   PubMed Web of Science ®Google Scholar
• TRAN CP, COOK GA, YEOMANS ND et al.: Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut (1999) 44:636-642.
   PubMed Web of Science ®Google Scholar
• STEINHART AH, BRZEZINSKI A, BAKER JP: Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am. J. Gastroenterol. (1994) 89:179-183.
   PubMed Web of Science ®Google Scholar
• BREUER RI, SOERGEL KH, LASHNER BA et al.: Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo controlled trial. Gut (1997) 40:485-491.
   PubMed Web of Science ®Google Scholar
• LEWIS JD, LICHTENSTEIN GR, DEREN JJ et al.: A randomized, placebo-controlled trial of the PPAR-γ ligand rosiglitazone for active ulcerative colitis. Gastroenterology (2007) 132:2585-2587 (late-breaking abstract).
   Google Scholar
• NISSEN SE, WOLSKI K: Effect of roziglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. (2007) 356:2457-2471.
   PubMed Web of Science ®Google Scholar
• HOME PD, POCOCK SJ, BECK-NIELSEN H et al.: Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N. Engl. J. Med. (2007) 357:28-38.
   PubMed Web of Science ®Google Scholar
• KAMM MA, SANDBORN WJ, GASSULL M et al.: Once daily, high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology (2007) 132:66-75.
   PubMed Web of Science ®Google Scholar
• SLONIM AE, BULONE L, DAMORE MB et al.: A preliminary study of growth hormone therapy for Crohn's disease. N. Engl. J. Med. (2000) 342:1633-1637.
   PubMed Web of Science ®Google Scholar
• SINHA A, NIGHTINGALE J, WEST KP et al.: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. (2003) 349:350-357.
   PubMed Web of Science ®Google Scholar
• WALLIS K, WALTERS JRF, FORBES A: Review article: glucagon-like peptide 2 – current applications and future directions. Aliment. Pharmacol. Ther. (2007) 25:365-372.
   PubMed Web of Science ®Google Scholar
• BUCHMAN AL, KATZ S, SHNAIDMAN, JACOBS D: Effect of teduglutide on patients with moderate-severe Crohn's disease after 8 weeks of therapy: a prospective, double-blind, placebo-controlled trial. Gastroenterology (2006) 131:949-950 (late-breaking abstract).
   Google Scholar
• ZHAO J, DE VERA J, NARUSHIMA S et al.: R-spondin 1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice. Gastroenterology (2007) 132:1331-1343.
   PubMed Web of Science ®Google Scholar
• MAHMOOD A, FITZGERALD AJ, MARCHBANK T et al.: Zinc carnosine, a health food supplement that stabilizes small bowel integrity and stimulates gut repair processes. Gut (2007) 56:168-175.
   PubMed Web of Science ®Google Scholar
• ZASLOFF M: Antimicrobial peptides in health and diseases. N. Engl. J. Med. (2002) 347:1199-1200.
   PubMed Web of Science ®Google Scholar
• RAMSEY RG, MICALLEF SJ, WILLIAMS B et al.: Colony-stimulating factor-1 promotes clonogenic growth of normal murine colonic crypt epithelia cells in vitro. J. Interferon Cytokine Res. (2004) 24:416-427.
   PubMed Web of Science ®Google Scholar
• KORZENIK JR, DIECKGRAEFE BK, VALENTINE JF et al.: Sargramostim for active Crohn's disease. N. Engl. J. Med. (2005) 352:2193-2201.
   PubMed Web of Science ®Google Scholar
• WAHL C, LIPTAY S, ADLER G et al.: Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J. Clin. Invest. (1998) 101:1163-1174.
   PubMed Web of Science ®Google Scholar
• SHAPIRO H, SINGER P, HALPERN Z, BRUCK R: Polyphenols in the treatment of inflammatory bowel disease and acute pancreatitis. Gut (2007) 56:426-435.
   PubMed Web of Science ®Google Scholar
• HANAI H, LIDA T, TAKEUCHI K et al.: Curcumin maintenance therapy in patients for ulcerative colitis: randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. (2006) 4:1502-1506.
   PubMed Web of Science ®Google Scholar
• DE VRY CG, PRASAD S, KOMUVES L et al.: Non-viral delivery of nuclear factor-κB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis. Gut (2007) 56:524-533.
   PubMed Web of Science ®Google Scholar
• ISOLAURI E, KIRJAVAINEN PV, SALMINEN S: Probiotics: a role in the treatment of intestinal infection and inflammation? Gut (2002) 50(Suppl. 3):II154-II159.
   Google Scholar
• BOUDEAU J, GLASSER A-L, JULIEN S et al.: Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment. Pharmacol. Ther. (2003) 18:45-56.
   PubMed Web of Science ®Google Scholar
• WEHKAMP J, HARDER J, WEHKAMP K et al.: NF-κB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect. Immun. (2004) 72:5750-5758.
   PubMed Web of Science ®Google Scholar
• GRABIG A, PACLIK D, GUZY C et al.: Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect. Immun. (2006) 74:4075-4082.
   PubMed Web of Science ®Google Scholar
• LLOPIS M, ANTOLIN M, GUARNER F et al.: Mucosal colonisation with Lactobacillus casei mitigates barrier injury induced by exposure to trinitrobenzene sulphonic acid. Gut (2005) 54:955-959.
   PubMed Web of Science ®Google Scholar
• ZAREIE M, JOHNSON-HENRY K, JURY J et al.: Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut (2006) 55:1553-1560.
   PubMed Web of Science ®Google Scholar
• YAN F, CAO H, COVER TL et al.: Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology (2007) 132:562-575.
   PubMed Web of Science ®Google Scholar
• MADSEN K, CORNISH A, SOPER P et al.: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterolgy (2001) 121:580-591.
   PubMed Web of Science ®Google Scholar
• PETROV EO, KOJIMA K, ROPELESKI MJ et al.: Probiotics inhibit nuclear factor-κB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology (2004) 127:1474-1487.
   PubMed Web of Science ®Google Scholar
• KANAUCHI O, SUGA T, TOCHIHARA M et al.: Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. J. Gastroenterol. (2002) 37(Suppl. XIV):67-72.
   PubMed Web of Science ®Google Scholar
• FURIE E, MACFARLANE S, KENNEDY A et al.: Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut (2005) 54:242-249.
   PubMed Web of Science ®Google Scholar
• BOUSVAROS A, GUANDALINI S, BALDASSANO RN et al.: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. (2005) 11:833-838.
   PubMed Web of Science ®Google Scholar
• MARTEAU P, LEMANN M, SEKSIK P et al.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut (2006) 55:842-847.
   PubMed Web of Science ®Google Scholar
• VAN GOSSUM A, DEWIT O, LOUIS E et al.: Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm. Bowel Dis. (2007) 13:135-142.
   PubMed Web of Science ®Google Scholar
• GUSLANDI M, MEZZI G, SORGHI M, TESTONI PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig. Dis. Sci. (2000) 45:1462-1464.
   PubMed Web of Science ®Google Scholar
• STEIDLER L, HANS W, SCHOTTE L et al.: Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 289:1352-1355.
   PubMed Web of Science ®Google Scholar
• BRAAT H, ROTTIERS P, HOMMES DW et al.: A Phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. (2006) 4:754-759.
   PubMed Web of Science ®Google Scholar
• VANDENBROUCKE K, HANS W, VAN HUYSSE J et al.: Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology (2004) 127:502-513.
   PubMed Web of Science ®Google Scholar
• KATO K, MIZUNO S, UMESAKI Y et al.: Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. (2004) 20:1133-1141.
   PubMed Web of Science ®Google Scholar
• KRUIS W, FRIC P, POKROTNIEKS et al.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 53:1617-1623.
   PubMed Web of Science ®Google Scholar
• MIMURA T, RIZZELLO F, HELWIG U et al.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 53:108-114.
   PubMed Web of Science ®Google Scholar
• GIONCHETTI P, RIZZELLO F, VENTURI A et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 119:305-309.
   PubMed Web of Science ®Google Scholar
• GIONCHETTI P, RIZZELLO F, HELWIG U et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 124:1202-1209.
   PubMed Web of Science ®Google Scholar
• SUMMERS RW, ELLIOTT DE, URBAN JF Jr et al.: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology (2005) 128:823-832.
   Google Scholar
• FIASSE R, LATINNE D: Intestinal helminths: a clue explaining the low incidence of inflammatory bowel diseases in Subsaharan Africa? Potential benefits and hazards of helminth therapy. Acta Gastroenterol. Belg. (2006) 69:418-422.
   PubMed Web of Science ®Google Scholar
• GONZALEZ-REY E, DELGADO M: Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology (2006) 131:1799-1811.
   PubMed Web of Science ®Google Scholar
• OYAMA Y, CRAIG RM, TRAYNOR AE et al.: Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology (2000) 119:1473-1482.
   PubMed Web of Science ®Google Scholar
• ALEXAKIS C, CARUELLE JP, SEZEUR A et al.: Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. A double-blind, placebo-controlled trial. Gut (2004) 53:85-90.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, LOFTUS EV, TREMAINE WJ et al.: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 126:19-31.
   PubMed Web of Science ®Google Scholar
• KAUR N, MAHL TC: Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig. Dis. Sci. (2007) 52:1481-1484.
   PubMed Web of Science ®Google Scholar
• ROSH JR, GROSS T, MAMULA P et al.: Heptosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. (2007) 13:1024-1030.
   PubMed Web of Science ®Google Scholar

Patents

• ISRAELSEN HANS: WO2007036230 (2007).
   Google Scholar
• NOVONORDISK AS: CA2196876 (1996).
   Google Scholar
• VERTEX PHARMA: WO9840064 (1998).
   Google Scholar
• SMITHKLINE BEECHAM PLC ET AL.: WO0062766 (2000).
   Google Scholar
• UNIV. CHICAGO: EP01595547 (2004).
   Google Scholar
• GASTRONE, INC.: WO9307891 (1993).
   Google Scholar
• NOVO NORDISK A/S: WO2006097536 (2006).
   Google Scholar
• KIRIN BREWERY CO. LTD ET AL.: WO2005072419 (2005).
   Google Scholar
• STANFORD UNIV.: WO2005032574 (2005).
   Google Scholar
• VERMALIS GROUP PIC: WO2005034950 (2005).
   Google Scholar
• UNIV. AUBURN ET AL.: WO2007065128 (2007).
   Google Scholar
• CEDAR SINAI MEDICAL CENTER: EP1748784 (2007).
   Google Scholar
• EXPANSCIENCE LAB: EP1763355 (2007).
   Google Scholar
• UNIV. WASHINGTON: JP2005225890 (2005).
   Google Scholar
• FIVE PRIME THERAPEUTICS, INC.: WO2006012451 (2006).
   Google Scholar
• CBR INSTITUTE FOR BIOCHEMICAL RESEARCH, INC.: WO2006119083 (2006).
   Google Scholar
• KENSIL CHARLOTTE: US2001034330 (2001).
   Google Scholar
• INNEX PHARMACEUTICALS CORP.: US2005191342 (2005).
   Google Scholar
• HADASI MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD: WO2005025596 (2003).
   Google Scholar
• EISAI CO. LTD: WO2005023792 (2005).
   Google Scholar
• UNIV. CHICAGO ET AL.: WO2005077389 (2005).
   Google Scholar
• UNIV. SOUTH FLORIDA ET AL.: WO2006110591 (2006).
   Google Scholar
• UNITED STATES GOVERNMENT: WO2006122242 (2005).
   Google Scholar
• PHARMACIA CORP.: WO2005040133 (2005).
   Google Scholar
• BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.: US20060073120 (2004).
   Google Scholar
• CBIO LTD: WO2005067959 (2005).
   Google Scholar
• CSL LTD: US2006019923 (2006).
   Google Scholar
• IDERA PHARMACEUTICALS, INC.: WO2007047396 (2007).
   Google Scholar
• BIO BALANCE CORP.: US2004067223 (2004).
   Google Scholar
• ALIMENTARY HEALTH LTD: US2006121015 (2006).
   Google Scholar
• LABORATOIRES BIOCODEX: US20060140973 (2004).
   Google Scholar
• MEIJI SEIKA KAISHA LTD: WO2006070891 (2006).
   Google Scholar
• ROWETT RES. INSTITUTE ET AL.: CA2519204 (2004).
   Google Scholar
• UNIV. COLLEGE CORK ET AL.: WO2005111194 (2005).
   Google Scholar
• NAT. INST. AGROBIO SCIENCES: JP2005154387 (2005).
   Google Scholar
• UNIV. GHENT ET AL.: WO2007025977 (2007).
   Google Scholar
• ITH IMMUNE THERAPY HOLDINGS AB ET AL.: WO2007027132 (2007).
   Google Scholar
• MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.: US20060093580 (2004).
   Google Scholar
• THERAPYX, INC.: US20050281885 (2004).
   Google Scholar
• SMITH CHARLES D ET AL.: US2006270630 (2006).
   Google Scholar
• HYBRIDON, INC.: CA2555105 (2005).
   Google Scholar
• NAT YANG MING UNIV.: US2006251739 (2006).
   Google Scholar